Gitnux/Report 2026

In Vivo Car-t Industry Statistics

The in vivo CAR-T market reached USD 861 million in 2026, explore growth, companies, and delivery trends across lentiviral and mRNA approaches.
14Statistics
30Sources
4Sections
1Visuals
15mRead
How this report is researched
01Editorial Scope

An editor sets the topic, the inclusion criteria, and the evaluation framework before research starts.

02Source Research

AI search agents locate sources and extract each figure together with the document it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 28 days

01 Industry overview

The in vivo car-t industry at a glance

The in vivo CAR-T industry is moving from preclinical research into early human testing, with indicative 2026 activity valued at $0.5–0.8 billion and long-term growth forecasts above 38% annually.

$0.5–0.8B[9]
Indicative 2026 market activity
38–42%[9]
2026–2036 forecast CAGR
≥50%[10]
Projected cost reduction
1.5–3 weeks[10]
Estimated manufacturing timeline
Market size
Indicative 2026 in vivo CAR-T industry activity is estimated at $0.5–0.8 billion, including development spending, acquisitions and partnerships, vector and lipid-nanoparticle manufacturing, and clinical supply. This is an early-stage market estimate rather than commercial product revenue, because no in vivo CAR-T therapy had received broad commercial approval by 2026.[9][10]
Forecast & CAGR
Meticulous Research estimates a 38–42% CAGR from 2026 to 2036, with indicative industry activity reaching $15–22 billion by 2036. A separate broader in vivo cell-therapy estimate projects a 49.6% CAGR from 2026 to 2033, but that market includes in vivo TCR engineering and other technologies beyond CAR-T.[9][11]
Market share & regions
Reliable public sources reviewed did not provide a defensible percentage split of the in vivo CAR-T market by region. The development landscape is international: a 2026 industry landscape identifies US, Chinese and European developers, while clinical studies are registered in the United States, Europe and China.[12][13]
Segmentation
The field is segmented primarily by delivery technology: integrating lentiviral vectors and transient mRNA lipid nanoparticles. Therapeutic development is concentrated in hematologic cancers such as B-cell malignancies and multiple myeloma, while autoimmune diseases are an expanding indication category.[14]
Key players & concentration
Key developers include Umoja Biopharma, Interius BioTherapeutics, EsoBiotec, Kelonia Therapeutics, Capstan Therapeutics, CREATE Medicines, Sana Biotechnology and Genocury. The field is becoming more concentrated through large-pharma transactions: Eli Lilly agreed in April 2026 to acquire Kelonia, while Johnson & Johnson announced a collaboration and exclusive acquisition option with Sail Biomedicines in July 2026.[14][15][16]
Pricing
No approved in vivo CAR-T product had an established market price in the sources reviewed. The commercial rationale is cost reduction: a 2026 review projects at least a 50% reduction in treatment-course costs compared with conventional approaches, while conventional CAR-T products are commonly cited at roughly $170,000–$509,000 per dose depending on product and pricing basis.[10][17]
Trends, drivers & challenges
The main drivers are elimination of patient-specific cell collection and ex vivo manufacturing, potentially shorter treatment preparation, and broader access to cell therapy. Core challenges remain selective delivery to T cells, off-target transduction, vector immunogenicity, control of CAR expression, cytokine-related toxicity, durability and the safety of integrating vectors.[10][18]
Consumer behavior & competition
There is no established consumer market because in vivo CAR-T candidates remain investigational and are accessed through clinical trials. Competition is instead concentrated among platform developers seeking differentiation through delivery selectivity, transient versus permanent expression, target-cell control and expansion into autoimmune diseases as well as cancer.[14][13]
M&A
M&A activity accelerated in 2026. Eli Lilly announced an agreement to acquire Kelonia Therapeutics, whose lead KLN-1010 was in Phase 1 for relapsed or refractory multiple myeloma; Johnson & Johnson separately announced strategic agreements with Sail Biomedicines, including an exclusive option to acquire the company.[15][16]
Regulation
In the United States, CAR-T products are regulated as human gene-therapy products, and FDA guidance covers chemistry, manufacturing and controls, pharmacology and toxicology, and clinical-study design. In vivo CAR-T developers must also address vector integration, long-term follow-up, biodistribution and risks from unintended cell modification; no in vivo CAR-T product had received FDA marketing approval in the sources reviewed.[19][10]
Latest news
The most significant 2026 developments were large-pharma dealmaking and clinical advancement. Lilly announced the Kelonia acquisition on April 20, 2026; Johnson & Johnson announced its Sail Biomedicines collaboration on July 29, 2026; and clinical-trial records showed new in vivo CAR-T studies, including a Phase I study registered in China in September 2026.[15][16][13]

02 Ranking

Top 10 Companies in the In Vivo Car-t Industry

The leading companies in the in vivo car-t industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 20, 2026 · Next review December 20, 2026

Verdict

Eli Lilly and Company stands out for in vivo CAR-T oncology and autoimmune portfolio building because it acquired Orna and Kelonia, while AstraZeneca leads in in vivo CAR-T and immune-cell development since it acquired EsoBiotec and its ENaBL in vivo lentiviral platform.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in in vivo CAR platforms

    Eli Lilly and Company

    US

    Ranked #1 · 9.9 · In vivo CAR platforms

    Why we picked it: It builds an in vivo CAR-T oncology and autoimmune portfolio after acquiring Orna and Kelonia.

  2. Leader in vector and mRNA delivery

    AstraZeneca

    GB

    Ranked #2 · 9.1 · Vector and mRNA delivery

    Why we picked it: It acquired EsoBiotec and the ENaBL in vivo lentiviral platform for in vivo CAR-T development.

  3. #3 overall

    AbbVie

    US

    Ranked #3 · 9.0 · In vivo CAR platforms

    Why we picked it: It acquired Capstan and a Phase 1 in vivo anti-CD19 CAR-T program in autoimmune-focused development.

Pick 1 is the #1 company overall. Pick 2 is the highest-ranked company in the top 5 that adds a new segment; no further segment places in the top 5, so pick 3 follows rank.

Full ranking

Sort by
Top 10 companies in the in vivo car-t industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Eli Lilly and Company

In vivo CAR platforms · US

9.9
2

AstraZeneca

Vector and mRNA delivery · GB

9.1
3

AbbVie

In vivo CAR platforms · US

9.0
4

Legend Biotech

In vivo CAR platforms · US

8.9
5

Gilead Sciences

In vivo CAR platforms · US

8.7
6

Umoja Biopharma

In vivo CAR platforms · US

8.7
7

CREATE Medicines

Vector and mRNA delivery · US

8.4
8

EXUMA Biotech

In vivo CAR platforms · US

8.1
9

Sana Biotechnology

In vivo CAR platforms · US

7.5
10

Aanastra

Vector and mRNA delivery · US

7.5

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 20, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 20). Top 10 companies in the in vivo car-t industry. In In Vivo Car-t Industry Statistics. Gitnux. https://gitnux.org/in-vivo-car-t-industry-statistics/#top-companies

report visual · Projection

Number of private financing transactions by companies developing in vivo CAR-T cell therapies

Number of private financing transactions by companies developing in vivo CAR-T cell therapies fell from 7 in 2020 to 6 in 2025.

7 count
Start
-3.04%
CAGR · 5y
6 count
Projected
20202025
source-verifiedwilliamblair.com2025

04 Statistics

Technology

Technology disclosures in 2025–2026 show a shift toward first-in-human Phase 1 work, with lentiviral and mRNA-LNP delivery approaches dominating the asset pipeline.

R&D, patents and design rights in the in vivo car-t industry

  • Approximately 75% of disclosed in-vivo CAR assets were preclinical in early 2025, while 7% had entered early clinical trials.[1]
  • More than 15 first-in-human Phase 1 trials for in-vivo CAR platforms had been registered in less than two years by 2026.[2]
  • More than 70 disclosed in-vivo CAR assets had accumulated globally by 2024, covering products and programs in development rather than approved therapies.[1]

05 Statistics

Market Intelligence

Market sizing in 2026 spans USD 861 million in category estimates and $0.5–0.8 billion in indicative industry activity, before large-scale commercial revenue exists.

Market size, volume and shipments in the in vivo car-t industry

  • USD 861 million was the estimated global 2026 in vivo CAR-T market size, covering the therapy category rather than conventional ex vivo CAR-T products.[3]
  • USD 136.2 million was the estimated global 2025 market size for in vivo CAR-T cell therapy, defined as net sales of administered vector or nanocarrier drug products generating CAR-T cells inside patients.[4]

Forecast growth and shipments in the in vivo car-t industry

  • 32.2% is the projected global CAGR for in vivo CAR-T cell therapy from 2026 through 2036, under a market definition excluding ex vivo products, licensing and acquisition payments.[4]
  • USD 10.8 billion is the projected global in vivo CAR-T market value for 2035, based on the category’s forecasted expansion from 2026.[3]
  • 32.5% is the projected global CAGR for in vivo CAR-T from 2026 through 2035, with market value forecast to rise from USD 861 million to USD 10.8 billion.[3]

06 Statistics

Strategy & Growth

Deal flow underpins strategy: Kite’s $350 million cash agreed for Interius in 2025 and AbbVie’s $2.1 billion cash consideration for Capstan in 2025.

M&A and consolidation in the in vivo car-t industry

  • $350 million in cash was agreed for Kite’s acquisition of Interius BioTherapeutics, an in vivo therapy platform company, in 2025.[5]
  • 4 acquisitions occurred in the in vivo CAR-T sector in 2025, with cumulative upfront payments of $4.5 billion, according to William Blair’s sector review.[6]
  • $2.1 billion was the announced cash consideration for AbbVie’s 2025 acquisition of Capstan Therapeutics, whose lead program was an in vivo targeted-lipid-nanoparticle CAR-T candidate.[7]

07 Statistics

Pricing & Finance

Cost reduction is treated as the main commercial lever, with projected ≥50% treatment-course cost reduction alongside financing activity such as Umoja’s $100 million Series C.

Capex and investment in the in vivo car-t industry

  • $100 million was raised in Umoja Biopharma’s Series C financing to advance its in vivo CAR-T pipeline and manufacturing-enabled VivoVec platform.[8]
  • $427 million was raised across six transactions by private companies developing in vivo CAR-T therapies year-to-date 2025, indicating current industry investment activity.[6]
  • $4.6 billion was raised by private companies developing in vivo CAR therapies from 2020 through 2025; this is industry investment, not physical-plant capex.[6]

Key questions about the in vivo car-t industry

How large is the in vivo CAR-T market in 2026?
The indicative 2026 in vivo CAR-T industry activity is valued at $0.5–0.8 billion, and one category estimate places global 2026 market size at USD 861 million.
What growth rate applies to the in vivo CAR-T market outlook?
Meticulous Research estimates a 38–42% CAGR from 2026 to 2036, and another in vivo CAR-T cell-therapy definition projects 32.2% CAGR from 2026 through 2036.
Which companies lead the in vivo car-t industry?
Eli Lilly and Company stands out for in vivo CAR-T oncology and autoimmune portfolio building because it acquired Orna and Kelonia, while AstraZeneca leads in in vivo CAR-T and immune-cell development since it acquired EsoBiotec and its ENaBL in vivo lentiviral platform.
What technology shift is visible in 2026 activity?
Development is segmented primarily by integrating lentiviral vectors and transient mRNA lipid nanoparticles, while clinical testing expands into Phase I.
How concentrated is the market structure and where does competition sit?
Competition is concentrated among platform developers seeking delivery selectivity, transient versus permanent expression, and CAR expression control, with development landscape activity across the US, China, and Europe.
What operational changes define the manufacturing and cost narrative for in vivo CAR-T?
Indicative manufacturing timelines are 1.5–3 weeks, and a 2026 review projects at least a 50% reduction in treatment-course costs versus conventional approaches.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 20). In Vivo Car-t Industry Statistics. Gitnux. https://gitnux.org/in-vivo-car-t-industry-statistics
MLA
Samuel Norberg. "In Vivo Car-t Industry Statistics." Gitnux, 20 Nov 2026, https://gitnux.org/in-vivo-car-t-industry-statistics.
Chicago
Samuel Norberg. 2026. "In Vivo Car-t Industry Statistics." Gitnux. https://gitnux.org/in-vivo-car-t-industry-statistics.